The abstract is read at the publisher; the summary is JClub's.
Tonlamarsen, a hepatocyte-directed antisense oligonucleotide targeting angiotensinogen (AGT), reduced circulating AGT by up to 75.2% after a single dose in healthy participants and patients with uncontrolled hypertension.
- Why it matters: Hypertension remains inadequately controlled, and there is a need for new strategies that suppress hepatic AGT to lower downstream blood-pressure drivers.
- What they did: In Phase 1 and 2a clinical studies, participants received single or monthly subcutaneous dosing; AGT changes were measured, and safety outcomes included platelet count, potassium, renal function, liver enzymes, and hypotension.
- The result: Monthly dosing produced AGT reductions up to 79.0% after 4 doses, with generally good tolerability and exploratory findings of lower systolic blood pressure versus placebo, supporting further hepatic AGT suppression evaluation.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.